3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
52
Lung Neoplasms
20
Neoplasms
4
Neoplasm Metastasis
3
Carcinoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Non Small Cell Lung Cancer Metastatic
1
NSCLC
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma
1
Interventions
durvalumab
3
abemaciclib
3
Fulvestrant
3
Cisplatin
3
ribociclib
2
pembrolizumab
2
palbociclib
2
Pemetrexed
2
Nivolumab
2
Letrozole
2
Carboplatin
2
Bevacizumab
2
Anastrozole
2
130-nm albumin-bound paclitaxel
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
Sunitinib
1
STX-478
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
osimertinib
×
90 days
×
Clear all
No trials found.